The final version of ICH E6(R3) took effect in the EU in July 2025 and in the UK and Canada in early 2026. While the FDA has not set a formal compliance deadline, the guideline represents the agency's current thinking and may be inspection-relevant for U.S. sites. The shift from checklist compliance to risk-based Quality by Design has direct implications for sponsors using AI tools to draft protocols. A 2026 study found baseline AI models generated factual errors in 18 to 43 percent of outputs when creating consent forms from protocols. E6(R3) requires sponsors to validate computerized systems, document data governance steps, and maintain audit trails. Sponsors retain full accountability for protocol quality regardless of vendor tools used. High-risk protocol sections addressing Critical to Quality factors require documented expert review, not just editorial passes. Sites should expect sponsors to demonstrate how AI-generated content was validated, reviewed by named experts, and controlled through each revision. The guideline's data governance provisions in Annex 1 apply by reasonable interpretation to any system generating trial-relevant regulatory content.